Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H18O11 |
| Molecular Weight | 458.3726 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
c1c(cc(c(c1O)O)O)[C@]2([H])[C@@]([H])(Cc3c(cc(cc3O2)O)O)OC(=O)c4cc(c(c(c4)O)O)O
InChI
InChIKey=WMBWREPUVVBILR-WIYYLYMNSA-N
InChI=1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2/t18-,21-/m1/s1
| Molecular Formula | C22H18O11 |
| Molecular Weight | 458.3726 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Epigallocatechin-3-gallate (EGCG), the major polyphenol from green tea, has the potential to impact a variety of human diseases. EGCG functions as a powerful antioxidant, preventing oxidative damage in healthy cells, but also as an antiangiogenic and antitumor agent and as a modulator of tumor cell response to chemotherapy. It was shown, that EGCG can inhibit 5-cytosine DNA methyltransferase (DNMT) activity and reactivate methylation-silenced genes in cancer cells and another of the probable mechanisms by EGCG exercise their anti-tumor property is through the suppression of the NFκB signaling pathway. EGCG has emerged as a potential neuroprotective agent for the treatment of neurological disorders associated with harmful effects of reactive oxygen species. The neuroprotective mechanism of action is probably based on several factors, including EGCG's modulation of several signal transduction pathways, its influence on the expression of genes regulating cell survival or programmed cell death, as well as its modulation of mitochondrial function. A phase II/III trial of oral Sunphenon epigallocatechin-3-gallate in patients with progressive multiple sclerosis has been completed. In addition, EGCG was in phase III clinical trials for the treatment of multiple system atrophy and for patients with Duchenne Muscular Dystrophy ((DMD). DMD is the most frequent neuromuscular condition to occur in childhood and youth.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P26358 Gene ID: 1786.0 Gene Symbol: DNMT1 Target Organism: Homo sapiens (Human) |
6.89 µM [Ki] | ||
Target ID: map04064 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Differential responses of skin cancer-chemopreventive agents silibinin, quercetin, and epigallocatechin 3-gallate on mitogenic signaling and cell cycle regulators in human epidermoid carcinoma A431 cells. | 2001 |
|
| Inhibition of melanoma growth and metastasis by combination with (-)-epigallocatechin-3-gallate and dacarbazine in mice. | 2001 |
|
| The 'pivotal antioxidant' hypothesis for the role of flavonoids in their reduction of HO* radical-induced damage on DNA. | 2001 |
|
| Green tea extracts decrease carcinogen-induced mammary tumor burden in rats and rate of breast cancer cell proliferation in culture. | 2001 |
|
| A new function of green tea: prevention of lifestyle-related diseases. | 2001 Apr |
|
| Prolyl endopeptidase inhibitors from green tea. | 2001 Aug |
|
| Metabolic fate of (-)-[4-(3)H]epigallocatechin gallate in rats after oral administration. | 2001 Aug |
|
| Modulation of gene expression by (-)-epigallocatechin gallate in PC-9 cells using a cDNA expression array. | 2001 Aug |
|
| The molecular interaction of human salivary histatins with polyphenolic compounds. | 2001 Aug |
|
| Potent antimutagenic activity of white tea in comparison with green tea in the Salmonella assay. | 2001 Aug 22 |
|
| Apoptosis induction by epigallocatechin gallate involves its binding to Fas. | 2001 Aug 3 |
|
| Involvement of ERK and protein tyrosine phosphatase signaling pathways in EGCG-induced cyclooxygenase-2 expression in Raw 264.7 cells. | 2001 Aug 31 |
|
| Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450. | 2001 Aug 8 |
|
| Anticarcinogenic antioxidants as inhibitors against intracellular oxidative stress. | 2001 Dec |
|
| Rapid conversion of tea catechins to monomethylated products by rat liver cytosolic catechol-O-methyltransferase. | 2001 Dec |
|
| Effect of polyphenols on calcium content and alkaline phosphatase activity in rat femoral tissues in vitro. | 2001 Dec |
|
| Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. | 2001 Dec |
|
| The green tea polyphenol (-)-epigallocatechin gallate attenuates beta-amyloid-induced neurotoxicity in cultured hippocampal neurons. | 2001 Dec 21 |
|
| Production of hydrogen peroxide and methionine sulfoxide by epigallocatechin gallate and antioxidants. | 2001 Jul-Aug |
|
| Changes in amino acid pool and utilization during apoptosis in HL-60 cells induced by epigallocatechin gallate or gallic acid. | 2001 Jul-Aug |
|
| Simultaneous determination of twelve tea catechins by high-performance liquid chromatography with electrochemical detection. | 2001 Jun |
|
| Development of an androgen reporter gene assay (AR-LUX) utilizing a human cell line with an endogenously regulated androgen receptor. | 2001 Nov 1 |
|
| Green tea epigallocatechin gallate: a natural inhibitor of fatty-acid synthase. | 2001 Nov 16 |
|
| Liquid chromatography with multi-channel electrochemical detection for the determination of epigallocatechin gallate in rat plasma utilizing an automated blood sampling device. | 2001 Nov 5 |
|
| Inhibitory effect of epigallocatechin gallate on adhesion of murine melanoma cells to laminin. | 2001 Nov 8 |
|
| The role of inducible nitric oxide synthase in cocaine-induced locomotor sensitization. | 2001 Nov-Dec |
|
| Inhibition of UVB-induced oxidative stress-mediated phosphorylation of mitogen-activated protein kinase signaling pathways in cultured human epidermal keratinocytes by green tea polyphenol (-)-epigallocatechin-3-gallate. | 2001 Oct 15 |
|
| Green tea constituent (--)-epigallocatechin-3-gallate inhibits topoisomerase I activity in human colon carcinoma cells. | 2001 Oct 19 |
|
| Simplified catechin-gallate inhibitors of HIV-1 reverse transcriptase. | 2001 Oct 22 |
|
| Inhibition by epigallocatechin gallate (EGCg) of conjugative R plasmid transfer in Escherichia coli. | 2001 Sep |
|
| A novel method of measuring hydroxyl radical-scavenging activity of antioxidants using gamma-irradiation. | 2001 Sep |
|
| Inhibitory activities of (-)-epigallocatechin-3-O-gallate against topoisomerases I and II. | 2001 Sep |
|
| Epigallocatechin gallate (EGCG) inhibits the sulfation of 1-naphthol in a human colon carcinoma cell line, Caco-2. | 2001 Sep |
|
| Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. | 2001 Sep |
|
| Epigallocatechin gallate synergy with ampicillin/sulbactam against 28 clinical isolates of methicillin-resistant Staphylococcus aureus. | 2001 Sep |
|
| Antioxidant activity and inhibitory effect of Gamazumi (Viburnum dilatatum THUNB.) on oxidative damage induced by water immersion restraint stress in rats. | 2001 Sep |
|
| Mechanisms of inhibition of the Ras-MAP kinase signaling pathway in 30.7b Ras 12 cells by tea polyphenols (-)-epigallocatechin-3-gallate and theaflavin-3,3'-digallate. | 2001 Sep |
|
| Effects of (-)-epigallocatechin-3-gallate, the main component of green tea, on the cloned rat brain Kv1.5 potassium channels. | 2001 Sep 1 |
|
| Cancer prevention with green tea and monitoring by a new biomarker, hnRNP B1. | 2001 Sep 1 |
|
| Epigallocatechin-3-gallate inhibits basic fibroblast growth factor-induced intracellular signaling transduction pathway in rat aortic smooth muscle cells. | 2002 Feb |
|
| Preformulation study of epigallocatechin gallate, a promising antioxidant for topical skin cancer prevention. | 2002 Jan |
|
| (-)Epigallocatechin-3-gallate inhibits leukocyte elastase: potential of the phyto-factor in hindering inflammation, emphysema, and invasion. | 2002 Jan |
|
| Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents. | 2002 Jan |
|
| Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1). | 2002 Jan |
|
| Hamamelitannin from Hamamelis virginiana inhibits the tumour necrosis factor-alpha (TNF)-induced endothelial cell death in vitro. | 2002 Jan |
|
| Potentiometric and (1)H NMR studies of complexation of Al(3+) with (-)-epigallocatechin gallate, a major active constituent of green tea. | 2002 Jan 1 |
|
| Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. | 2002 Jan 15 |
|
| In vitro therapeutic effect of epigallocatechin gallate on nicotine-induced impairment of resistance to Legionella pneumophila infection of established MH-S alveolar macrophages. | 2002 Jan 15 |
|
| Green tea polyphenol stimulates a Ras, MEKK1, MEK3, and p38 cascade to increase activator protein 1 factor-dependent involucrin gene expression in normal human keratinocytes. | 2002 Jan 18 |
|
| Synergistic effects of (-)-epigallocatechin gallate with sulindac against colon carcinogenesis of rats treated with azoxymethane. | 2002 Mar 8 |
Sample Use Guides
Sunphenon EGCG (Epigallo Catechin Gallate) 200-800mg (1-4 capsules)
Route of Administration:
Oral
Epigallocatechin gallate (EGCG) could inhibit the viability and invasion, and induce the apoptosis, of bladder cancer T24 cells. The apoptosis of bladder cancer cells was notably increased by 20 µm EGCG. In addition, 20 µm EGCG inhibited bladder cancer cell viability. However, 10 µm EGCG did not exhibit any significant inhibitory effect on T24 cell viability. The effect of EGCG on the invasive ability of the bladder cancer cells was then investigated, which demonstrated that 10 µm and 20 µm of EGCG significantly inhibited invasion compared with the control group.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 21:27:39 UTC 2021
by
admin
on
Fri Jun 25 21:27:39 UTC 2021
|
| Record UNII |
BQM438CTEL
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C68454
Created by
admin on Fri Jun 25 21:27:39 UTC 2021 , Edited by admin on Fri Jun 25 21:27:39 UTC 2021
|
||
|
DSLD |
2960 (Number of products:2)
Created by
admin on Fri Jun 25 21:27:39 UTC 2021 , Edited by admin on Fri Jun 25 21:27:39 UTC 2021
|
||
|
DSLD |
1193 (Number of products:210)
Created by
admin on Fri Jun 25 21:27:39 UTC 2021 , Edited by admin on Fri Jun 25 21:27:39 UTC 2021
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1236700
Created by
admin on Fri Jun 25 21:27:39 UTC 2021 , Edited by admin on Fri Jun 25 21:27:39 UTC 2021
|
PRIMARY | USP-RS | ||
|
65064
Created by
admin on Fri Jun 25 21:27:39 UTC 2021 , Edited by admin on Fri Jun 25 21:27:39 UTC 2021
|
PRIMARY | |||
|
C1088
Created by
admin on Fri Jun 25 21:27:39 UTC 2021 , Edited by admin on Fri Jun 25 21:27:39 UTC 2021
|
PRIMARY | |||
|
DB12116
Created by
admin on Fri Jun 25 21:27:39 UTC 2021 , Edited by admin on Fri Jun 25 21:27:39 UTC 2021
|
PRIMARY | |||
|
EPIGALLOCATECHIN GALLATE
Created by
admin on Fri Jun 25 21:27:39 UTC 2021 , Edited by admin on Fri Jun 25 21:27:39 UTC 2021
|
PRIMARY | |||
|
989-51-5
Created by
admin on Fri Jun 25 21:27:39 UTC 2021 , Edited by admin on Fri Jun 25 21:27:39 UTC 2021
|
PRIMARY | |||
|
BQM438CTEL
Created by
admin on Fri Jun 25 21:27:39 UTC 2021 , Edited by admin on Fri Jun 25 21:27:39 UTC 2021
|
PRIMARY | |||
|
SUB33667
Created by
admin on Fri Jun 25 21:27:39 UTC 2021 , Edited by admin on Fri Jun 25 21:27:39 UTC 2021
|
PRIMARY | |||
|
M4843
Created by
admin on Fri Jun 25 21:27:39 UTC 2021 , Edited by admin on Fri Jun 25 21:27:39 UTC 2021
|
PRIMARY | Merck Index | ||
|
C045651
Created by
admin on Fri Jun 25 21:27:39 UTC 2021 , Edited by admin on Fri Jun 25 21:27:39 UTC 2021
|
PRIMARY | |||
|
989-51-5
Created by
admin on Fri Jun 25 21:27:39 UTC 2021 , Edited by admin on Fri Jun 25 21:27:39 UTC 2021
|
PRIMARY | |||
|
24246
Created by
admin on Fri Jun 25 21:27:39 UTC 2021 , Edited by admin on Fri Jun 25 21:27:39 UTC 2021
|
PRIMARY | RxNorm |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT | |||
|
TRANSPORTER -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
